vs
Side-by-side financial comparison of Baxter International (BAX) and Intercontinental Exchange (ICE). Click either name above to swap in a different company.
Intercontinental Exchange is the larger business by last-quarter revenue ($3.1B vs $3.0B, roughly 1.1× Baxter International). Intercontinental Exchange runs the higher net margin — 27.1% vs -37.9%, a 65.0% gap on every dollar of revenue. On growth, Baxter International posted the faster year-over-year revenue change (458.0% vs 3.7%). Over the past eight quarters, Intercontinental Exchange's revenue compounded faster (5.9% CAGR vs -9.0%).
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
Intercontinental Exchange, Inc. (ICE) is an American multinational financial services company formed in 2000 that operates global financial exchanges and clearing houses and provides mortgage technology, data and listing services. Listed on the Fortune 500, S&P 500, and Russell 1000, the company owns exchanges for financial and commodity markets, and operates 12 regulated exchanges and marketplaces. This includes ICE futures exchanges in the United States, Canada, and Europe; the Liffe future...
BAX vs ICE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.0B | $3.1B |
| Net Profit | $-1.1B | $851.0M |
| Gross Margin | 19.4% | — |
| Operating Margin | -24.5% | 39.4% |
| Net Margin | -37.9% | 27.1% |
| Revenue YoY | 458.0% | 3.7% |
| Net Profit YoY | -120.3% | 21.9% |
| EPS (diluted) | $-2.21 | $1.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.0B | $3.1B | ||
| Q3 25 | $2.8B | $3.0B | ||
| Q2 25 | $2.8B | $3.3B | ||
| Q1 25 | $2.6B | $3.2B | ||
| Q4 24 | $533.0M | $3.0B | ||
| Q3 24 | $2.7B | $3.0B | ||
| Q2 24 | $3.8B | $2.9B | ||
| Q1 24 | $3.6B | $2.8B |
| Q4 25 | $-1.1B | $851.0M | ||
| Q3 25 | $-46.0M | $816.0M | ||
| Q2 25 | $91.0M | $851.0M | ||
| Q1 25 | $126.0M | $797.0M | ||
| Q4 24 | $-512.0M | $698.0M | ||
| Q3 24 | $140.0M | $657.0M | ||
| Q2 24 | $-314.0M | $632.0M | ||
| Q1 24 | $37.0M | $767.0M |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 33.5% | — | ||
| Q2 25 | 35.3% | — | ||
| Q1 25 | 32.8% | — | ||
| Q4 24 | 25.0% | — | ||
| Q3 24 | 38.3% | — | ||
| Q2 24 | 37.5% | — | ||
| Q1 24 | 38.6% | — |
| Q4 25 | -24.5% | 39.4% | ||
| Q3 25 | 6.1% | 39.0% | ||
| Q2 25 | 6.8% | 39.8% | ||
| Q1 25 | 2.2% | 37.8% | ||
| Q4 24 | -25.5% | 35.5% | ||
| Q3 24 | 5.7% | 36.4% | ||
| Q2 24 | -5.0% | 36.8% | ||
| Q1 24 | 5.2% | 38.0% |
| Q4 25 | -37.9% | 27.1% | ||
| Q3 25 | -1.6% | 27.1% | ||
| Q2 25 | 3.2% | 26.1% | ||
| Q1 25 | 4.8% | 24.7% | ||
| Q4 24 | -96.1% | 23.0% | ||
| Q3 24 | 5.2% | 21.7% | ||
| Q2 24 | -8.2% | 21.8% | ||
| Q1 24 | 1.0% | 27.4% |
| Q4 25 | $-2.21 | $1.49 | ||
| Q3 25 | $-0.09 | $1.42 | ||
| Q2 25 | $0.18 | $1.48 | ||
| Q1 25 | $0.25 | $1.38 | ||
| Q4 24 | $-0.99 | $1.21 | ||
| Q3 24 | $0.27 | $1.14 | ||
| Q2 24 | $-0.62 | $1.10 | ||
| Q1 24 | $0.07 | $1.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | $837.0M |
| Total DebtLower is stronger | $9.5B | — |
| Stockholders' EquityBook value | $6.1B | $28.9B |
| Total Assets | $20.1B | $136.9B |
| Debt / EquityLower = less leverage | 1.55× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0B | $837.0M | ||
| Q3 25 | $1.7B | $850.0M | ||
| Q2 25 | $1.7B | $1.0B | ||
| Q1 25 | $2.3B | $783.0M | ||
| Q4 24 | $1.8B | $844.0M | ||
| Q3 24 | $1.4B | $755.0M | ||
| Q2 24 | $2.1B | $885.0M | ||
| Q1 24 | $3.0B | $863.0M |
| Q4 25 | $9.5B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.4B | — | ||
| Q3 24 | $10.4B | — | ||
| Q2 24 | $10.4B | — | ||
| Q1 24 | $11.1B | — |
| Q4 25 | $6.1B | $28.9B | ||
| Q3 25 | $7.2B | $28.6B | ||
| Q2 25 | $7.3B | $28.4B | ||
| Q1 25 | $7.1B | $28.0B | ||
| Q4 24 | $7.0B | $27.6B | ||
| Q3 24 | $7.9B | $27.2B | ||
| Q2 24 | $7.6B | $26.7B | ||
| Q1 24 | $8.2B | $26.2B |
| Q4 25 | $20.1B | $136.9B | ||
| Q3 25 | $21.1B | $140.9B | ||
| Q2 25 | $21.0B | $144.2B | ||
| Q1 25 | $21.3B | $142.9B | ||
| Q4 24 | $25.8B | $139.4B | ||
| Q3 24 | $26.7B | $135.2B | ||
| Q2 24 | $26.3B | $137.7B | ||
| Q1 24 | $27.8B | $131.4B |
| Q4 25 | 1.55× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $584.0M | $1.3B |
| Free Cash FlowOCF − Capex | — | $1.1B |
| FCF MarginFCF / Revenue | — | 35.3% |
| Capex IntensityCapex / Revenue | — | 5.3% |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | $4.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $584.0M | $1.3B | ||
| Q3 25 | $237.0M | $915.0M | ||
| Q2 25 | $217.0M | $1.5B | ||
| Q1 25 | $-193.0M | $966.0M | ||
| Q4 24 | $488.0M | $1.5B | ||
| Q3 24 | $253.0M | $898.0M | ||
| Q2 24 | $115.0M | $1.2B | ||
| Q1 24 | $163.0M | $1.0B |
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $853.0M | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $881.0M | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $819.0M | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $951.0M |
| Q4 25 | — | 35.3% | ||
| Q3 25 | — | 28.4% | ||
| Q2 25 | — | 44.3% | ||
| Q1 25 | — | 27.3% | ||
| Q4 24 | — | 43.3% | ||
| Q3 24 | — | 27.0% | ||
| Q2 24 | — | 38.7% | ||
| Q1 24 | — | 34.0% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 2.6% | ||
| Q4 24 | — | 6.4% | ||
| Q3 24 | — | 2.6% | ||
| Q2 24 | — | 2.6% | ||
| Q1 24 | — | 2.1% |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | 1.12× | ||
| Q2 25 | 2.38× | 1.77× | ||
| Q1 25 | -1.53× | 1.21× | ||
| Q4 24 | — | 2.16× | ||
| Q3 24 | 1.81× | 1.37× | ||
| Q2 24 | — | 1.89× | ||
| Q1 24 | 4.41× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
ICE
| Other | $1.9B | 60% |
| Fixed Income Data And Analytics | $318.0M | 10% |
| Exchange Data | $266.0M | 8% |
| Origination Technology | $188.0M | 6% |
| Financial Futures And Options | $155.0M | 5% |
| Listings | $125.0M | 4% |
| OT Cand Other Transactions | $97.0M | 3% |
| Closing Solutions | $60.0M | 2% |
| Fixed Income Execution | $29.0M | 1% |
| Product And Service Net Interest Income | $26.0M | 1% |
